Mr. Vasant Narasimhan has been the Chief Executive Officer of the company since 2018. Prior to this, he served as the Global Head Drug Development and the Chief Medical Officer of the company. He is also a member of the Executive Committee of Novartis. Mr. Narasimhan held several leadership positions in the development and commercial functions. He also held the position of Global Head of Development of Novartis Pharmaceuticals; and Global Development Head at Novartis Vaccines. In the past, he led the Sandoz biosimilars and oncology injectables business unit. Prior to Novartis, Mr. Narasimhan worked at McKinsey & Company.

Mr. Mukul Mehta has been the Chief Financial Officer of the company since March 2026. Prior to this, he served as the Head of Business Planning and Analysis of Digital Finance and Tax; Chief Financial Officer of International Business; Chief Financial Officer of the company's Pharmaceuticals Business. Previously, he served as the Chief Financial Officer of Novartis Business Services; Chief Financial Officer of Pharmaceuticals Europe Business; and Country Chief Financial Officer of France, Poland, and Norway.

Mr. Shreeram Aradhye has been the Chief Medical Officer and President of Global Drug Development of the company since 2022. Prior to this, he served as the Executive Vice President and Chief Medical Officer at Dicerna Therapeutics. Previously, he served as the Executive Vice President & Chief Development Officer at Axcella Health from 2019 to 2020. Mr. Aradhye has served as Global Head, Medical Affairs and Chief Medical Officer of Pharmaceuticals at Novartis from 2017 to 2019 and Global Head of Development Franchise Neuroscience, and the US Head of Development from 2013 to 2017. Mr. Aradhye has served as the Head of Global Clinical Development & Medical Affairs at Biosimilars, Sandoz, Germany from 2009 to 2011.

Ms. Karen L. Hale has been the Chief Legal and Compliance Officer of the company since 2025. Prior to this, she served as the Chief Legal Officer of the company and in several leadership roles, including as the Vice President, Deputy General Counsel, Chief Ethics and Compliance Officer, and Divisional Vice President at AbbVie Inc.

Mr. Robert Kowalski has been the Chief People & Organization Officer of the company since 2021. Prior to this, he served as the Executive Vice President, Global Head of Regulatory, US Head of Global Drug Development for Novartis Pharmaceuticals Corp; Ad interim President for Novartis Corp; Ad interim Head of Global Drug Development and Chief Medical Officer of the company. Previously, he served as the Senior Vice President and Head of Regulatory Affairs for Novartis Pharmaceuticals Corp; Senior Vice President and Head of Regulatory Affairs for Novartis Pharma AG. Mr. Kowalski also served as the Global Head of Country Medical Development for Novartis Pharmaceuticals Corp.